Clinical trial
A Phase 1/2, Randomized, Placebo-Controlled, Double-Blind, Dose-Finding, First-in-Human Study of Respiratory Syncytial Virus (RSV) mRNA Vaccine STR-V003 in Healthy Adults
NCT06344975 is registered in ClinicalTrials.gov with Starna Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, Randomized, Placebo-Controlled, Double-Blind, Dose-Finding, First-in-Human Study of Respiratory Syncytial Virus (RSV) mRNA Vaccine STR-V003 in Healthy Adults
- Lead sponsor
- Starna Therapeutics
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- May 31, 2024
- Completion date
- May 31, 2025
- Enrollment
- 48 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.